Aims The effect of low-density lipoprotein cholesterol-lowering therapy with alirocumab or
evolocumab on individual clinical efficacy and safety endpoints remains unclear. We aimed …

Heart failure (HF) is a complex clinical syndrome caused by various cardiovascular
diseases. Its main pathogenesis includes cardiomyocyte loss, myocardial energy …

Background: Genetic screening programs in unselected individuals with increased levels of
low-density lipoprotein cholesterol (LDL-C) have shown modest results in identifying …

Aims Proprotein convertase subtilisin kexin 9 (PCSK9) is an emerging target for the
treatment of hypercholesterolaemia, but the clinical utility of PCSK9 levels to guide treatment …

Atherosclerosis is the key pathogenesis of cardiovascular disease, which is a silent killer
and a leading cause of death in the United States. Atherosclerosis starts with the adhesion …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulating
lipoprotein metabolism by binding to low-density lipoprotein receptors (LDLRs), leading to …

Introduction Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of global
mortality, imposing substantial healthcare economic burdens. Among the modifiable risk …

Atherosclerosis is initiated by the subendothelial accumulation of apoB-lipoproteins, which
initiates a sterile inflammatory response dominated by monocyte–macrophages but …

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted zymogen expressed
primarily in the liver. PCSK9 circulates in plasma, binds to cell surface low-density …

Previous work from the European Society of Cardiology (ESC), the European
Atherosclerosis Society (EAS) and from other groups has addressed the benefits of statin …